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Abstract
Background: The Hypertension in the Very Elderly Trial (HYVET) is a placebo controlled double blind
trial of treating hypertension with indapamide Slow Release (SR) ± perindopril in subjects over the age of
80 years. The primary endpoints are stroke (fatal and non fatal). In view of the fact that thiazide diuretics
and indapamide reduce urinary calcium and may increase bone mineral density, a fracture sub study was
designed to investigate whether or not the trial anti-hypertensive treatment will reduce the fracture rate
in very elderly hypertensive subjects.
Methods: In the trial considerable care is taken to ascertain any fractures and to identify risk factors for
fracture, such as falls, co-morbidity, drug treatment, smoking and drinking habits, levels of activity,
biochemical abnormalities, cardiac irregularities, impaired cognitive function and symptoms of orthostatic
hypotension.
Potential results: The trial is expected to provide 10,500 patient years of follow-up. Given a fracture rate
of 40/1000 patient years and a 20% difference in fracture rate, the power of the sub study is 58% to detect
this difference at the 5% level of significance. The corresponding power for a reduction of 25% is 78%.
Conclusion: The trial is well under way, expected to complete in 2009, and on target to detect, if present,
the above differences in fracture rate.
Background
Fragility fractures are associated not only with trauma but
with a reduced bone mineral density (BMD), a low level
of calcium intake, low concentration of vitamin D in the
blood and a high loss of calcium in the urine [1-3]. A high
loss of calcium in the urine is also associated with stone
formation in the renal tract probably with calcium phos-
phate as the core ingredient. Hypertensive subjects are
particularly vulnerable to calcium stone risk [4,5].
The prevention of osteoporosis and an increase in BMD is
achieved therapeutically by increasing calcium intake,
increasing vitamin D intake and production in the skin,
increasing bone formation or by inhibiting resorption of
bone.
Diuretics, such as thiazides increase the passive absorp-
tion of calcium in the proximal renal tubules [6] and
therefore reduce calcium excretion [7]. It has been sug-
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gested that calcium is reabsorbed owing to a reduction in
extracellular volume [8]. The effects are employed thera-
peutically in the prevention of renal stones and benefits
have been shown in 3 trials [9-11] with one failing to find
a benefit [12]. Indapamide, a sulphonamide related to the
thiazide diuretics also reduces calcium excretion and renal
stones [13-18]. Two randomised trials suggest that the use
of a thiazide diuretic may preserve BMD [19,20] and
observational studies suggest they may reduce the inci-
dence of fracture [21-24] but not all studies support this
view [25] Results from a meta-analysis suggested that
long-term thiazide use may be protective against hip frac-
ture but was not conclusive (OR 0.82, 95% CI 0.62–1.08)
[26]. The situation is complicated by the fact that a high
oral sodium intake also increases urinary calcium excre-
tion [27]. It has been suggested that indapamide SR may
also prevent fractures and indapamide SR is the first line
treatment in the placebo controlled Hypertension in the
Very Elderly Trial (HYVET) [28]. A sub-study was devel-
oped to determine whether or not indapamide prevents
fractures in these elderly (≥80 years) hypertensive sub-
jects. The HYVET trial is designed to follow-up subjects for
10,500 patient years. In their meta-analysis, Jones et al
concluded that a trial of a diuretic to reduce hip fractures
by 20% at the 5% level significance in men and women
over the age of 70 in the lowest quintile of femoral neck
density would require 7,000 patient years with 80%
power [26]. The HYVET trial includes subjects only over
age 80 and covers all types of fracture but does not include
densitometry to identify a low quintile of bone density.
This article describes the protocol for the first randomised
placebo controlled trial sub study that investigates
whether or not indapamide 1.5 mg sustained release
reduces the incidence of fractures, a secondary endpoint
in the HYVET trial.
Protocol
Brief overview of the HYVET main trial protocol
The HYVET main trial randomises patients with an aver-
age systolic blood pressure (over 2 months on placebo) of
160–199 mm Hg and a diastolic pressure <110 mm Hg.
Patients must be over the age of 80, have a standing systo-
lic pressure ≥140 mm Hg and with no evidence of renal
failure or co-morbidity requiring anti-hypertensive treat-
ment. The full protocol, including all inclusion and exclu-
sion criteria has been published [28]. On randomisation
patients are treated using the double-blind method either
with indapamide SR 1.5 mg or matching placebo. If goal
blood pressure (<150 mm Hg systolic and <80 mm Hg
diastolic) is not achieved perindopril 2–4 mg or matching
placebo is added as appropriate. The patients are fol-
lowed-up both according to clinical need and every 3
months in the first year and every 6 months thereafter. At
each of these visits data are collected on blood pressure
and any events that have occurred since the previous visit.
Serious adverse effects are reported as they occur. Blood
tests, including serum electrolytes and blood glucose, and
quality of life assessments are made annually. The patient
may be followed up for a period of 6 months to seven
years, depending on date of entry to the trial. The trial has
approval of the National and Local Ethical Committees as
required.
Protocol for HYVET Fracture Sub-Study
The trial documents are designed to maximise the report-
ing of fractures, to identify those factors that are recog-
nised as strongly associated with fracture incidence and to
validate the occurrence of any reported fracture.
1. The ascertainment of fractures
The entry form asks for details of all fractures in the previ-
ous 20 years including the site of fractures and year of
occurrence. This past history may not be complete owing
to failure to recall an event. The interim forms (completed
after 3,6,9, months and hen six monthly) and the annual
forms (completed each year from 12 months until the end
of the study) ask for diseases or events since the last visit,
including fractures or operations, and is expected to pro-
vide almost 100% ascertainment of fractures in those who
remain in follow-up.
2. The identification of risk factors for fractures
a) Falls
The Interim and annual forms ask 'Has the patient fallen
since the last visit?' and 'If yes how many falls?'.
b) Associated co-morbidity
The entry form asks for current diseases and typical
responses include rheumatoid arthritis and osteoarthritis
of the hips. The form also asks for other serious past dis-
eases and past major operations. The interim and annual
forms ask for diseases or events since the last visit.
c) Associated drug treatment
The entry form asks for the drugs currently being taken
including daily dose and year started. The interim and
annual forms ask for current drugs taken including aspi-
rin, other analgesics and laxatives etc.
It is expected that drugs associated with falls such as anxi-
olytics [29] and anti-depressants [30] will be identified by
these questions, although these drugs may not be associ-
ated with a low BMD [31].
d. Symptoms
Symptoms such as light headedness and dizziness may be
associated with falls and fractures. Information on these
are specifically addressed in the Quality of Life (QOL)
forms administered at baseline and annually thereafter.
The QOL sub study currently involves 65% of subjects. At
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baseline and on the interim and annual forms the investi-
gators are also asked to record any symptoms reported by
the patients.
e. Smoking and drinking habits
Smoking is associated with vascular disease that may pre-
cipitate falls and alcohol has a direct effect in inducing
falls. Details of smoking habits including number of ciga-
rettes consumed per day, and the number of alcoholic
drinks consumed per week are recorded at baseline and
on the annual forms.
f. Activity
The amount of activity undertaken and the necessity for
help during activity are both related to the probability of
a fall. The living arrangements, for example in sheltered
accommodation, are recorded on the entry, interim and
annual forms. Activities of daily living (ADLs) are
recorded on the entry and annual forms and include the
necessity for assistance with bathing, dressing, going to
the toilet and walking along the street.
g. Biochemical abnormalities
Biochemical abnormalities such as a low serum sodium
are related to falls [32] and are recorded at entry and
annually. Blood glucose is also recorded and a high con-
centration may relate directly to falls or via retinopathy or
neuropathy.
h. Heart block and atrial fibrillation
Patients with heart block and irregularities of cardiac
rhythm have a greater propensity to fall. A standard elec-
trocardiographic tracing is recorded at baseline and annu-
ally thereafter to determine these abnormalities and the
incidence of myocardial infarction and other cardiac
events.
i. Impaired cognitive function
Subjects with an impaired cognitive function are recog-
nised to be more at risk of falls [33]. At entry to the trial
and annually thereafter the Orientation Memory Concen-
tration (OMC) [34] and Mini Mental State Examination
(MMSE) [35] test results are recorded to determine cogni-
tive function. These tests are supplemented by the Clock
Drawing Test [36] and Geriatric Depression Scale [37]
assessments contained in the QOL forms.
3. Power of the sub-study
Maravic et al [38] have reported the incidence of limb frac-
tures leading to hospitalization in French men and
women over the age of 81 occurring in 2001. They consid-
ered fractures of the hip, proximal humerus and distal
radius and/or ulna. The fracture rate for women ≥ 81 years
was 2475/million for the humerus, 4256/million for the
radius/ulna and 25,846/million for hip fracture. This
equates to roughly 3.3%/year. Assuming many fractures
of the radius or ulna will not require hospitalization the
fracture rate may well be in the region of 4%/year in
women. The corresponding figure in men appeared to be
about 1.5%/year. In a prospective population based study
in Rotterdam the annual incidence of all non -vertebral
fracture in subjects aged 80 to 85 years old was 2% in men
and more than 3% in women. The fracture incidence was
still increased in the subjects that were aged more than 85
years old reaching around 3% in men and 5% in women.
[39]. As two thirds of HYVET subjects are women the
peripheral fracture rate may be expected to be in the
region of 40/1000/year.
The incidence of vertebral fractures in the very elderly is
unclear. The annual incidence of vertebral deformity in
the Rotterdam study in subjects aged more than 75 was
1.96% in women and 0.9% in men [39]. However in the
HYVET trial we do not have radiology of the spine at base-
line and it will be difficult to evaluate incident vertebral
fractures. We have excluded vertebral fractures from our
calculations.
Assuming a fracture rate of 40/1000/years (excluding ver-
tebral fractures) and a 20% difference in fracture rate as
suggested by Jones et al [26], 10,500 patient years (the tar-
get for the main HYVET trial) should detect this reduction
at the 5% level of significance and a power of 58%. A 25%
reduction would be detected with a power of 78%. These
estimates may be conservative as the incidence of fragility
(low trauma) fractures may be increasing [40,41] possibly
independently of the ageing of the population [40].
4. Validation of Fracture Events
The End Point Committee examines reports of fractures
and supplementary information such as radiology reports
or operation notes. The Committee (constitution given in
the acknowledgements) validates fracture reports as
i) Fracture – validated
ii) Probable fracture unconfirmed – unable to confirm.
iii) No fracture – error in diagnosis
Discussion
The HYVET sub-study on fractures is the largest placebo-
controlled trial of thiazide type diuretic treatment in the
prevention of fractures to have been started to date. The
risks and benefits of anti-hypertensive treatment in the
very elderly (over age 80) hypertensive has yet to be deter-
mined. The results of the pilot trial [42], namely that for
every stroke prevented there was one extra non-stroke
death agree with the results of the INDANA meta-analysis
[43]. Thus, if the main trial should show both risks and
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benefits of treatment, other outcomes may have to be con-
sidered. These include any reduction in fracture rate, and
any improvement (or deterioration) in cognitive function
and quality of life. The very elderly may (or may not) have
a greater interest in the prevention of fractures, strokes,
and cognitive impairment than in the prolongation of life.
The HYVET trial and its sub-studies therefore aim to give
a rounded picture of what are the benefits and risks of anti
hypertensive treatment in the very elderly, specifically
those with mild to moderate hypertension who do not
have heart failure or certain other complications of hyper-
tension. The fracture sub-study is an integral part of the
complete picture although not the primary end-point of
the HYVET trial. The strengths of the sub-study are the
inclusion of a high risk (very elderly) group and the
attempts to gain full ascertainment and validation of frac-
ture events. A possible, and as yet unconfirmed, weakness
is that subjects may be recruited who are of above average
fitness for their age group and thus lacking the expected
fracture incidence. If this proves true then a trial needs to
be performed in patients at even higher risk, for example
the very elderly with previous fractures, who do not have
a 'low' blood pressure. The HYVET study will also fail to
detect many vertebral fractures. The Clinical Research
Forms do not ask specifically about back pain and there is
no routine radiology. We do, however, base our power
calculations only on clinically detected peripheral frac-
tures.
There are reasons to expect a benefit in preventing frac-
tures as diuretics reduce the amount of calcium in the
urine. In spontaneously hypertensive rats given large
doses (1.5 mg/kg/day) of indapamide SR and a high salt
intake, urinary calcium was decreased, sodium excretion
increased and sodium-induced bone loss was prevented
[44]. The studies in man suggest that thiazide diuretics
and indapamide SR reduce calcium excretion in the urine
by about 40–50% in patients with hypercalcuria and, in a
very small study of patients with essential hypertension,
reduce calcium excretion by about 20% [16].
It is relevant and interesting that renal stone production
has been reduced by the use of diuretics in some trials but
not in others. Four positive trials have been reported that
employed hydrochlorothiazide [9] bendroflumethiazide
[10] chlorthalidone [11] and indapamide 2.5 mg/day
[15]. In the latter study stone formation was reduced by
0.2 stones/per patient/per year and the relative risk for
remaining stone free with indapamide was 1.5. The
HYVET trial, however, is not powered to detect a reduction
in the rare event of passing renal stones.
Are there already data to prove that diuretics prevent frac-
tures? To our knowledge there have not been any ran-
domised controlled trials of the effects of diuretic
treatment on the rate of fractures. Nevertheless there have
been cross-sectional and longitudinal studies that have
been summarised in a meta-analysis [26]. These studies
suggested a 20% reduction in hip fracture. On the other
hand one case control study reported a 60% increased risk
of hip fracture [45]. A meta-analysis of longitudinal stud-
ies obviously carries more weight than one case control
study.
Recently a pharmacoepidemiologic case-control study of
the Danish population [22] reported on 64,699 patients
over age 40 with fractures. 194,111 controls used less cor-
ticosteroids, thyroxine, anxiolytics, antidepressants and
diuretics than the cases. Thiazide diuretics were taken by
22% of controls and 23.7% of cases. However the thiazide
users were older, more often women, took more of the
other drug groups and had had more previous fractures
than non-users. Thus for current users of thiazide diuret-
ics, a crude odds ratio of 1.03 for getting any fracture was
reduced to 0.90 (95%CI 0.88–0.93) by full adjustment
[22]. When only those subjects who had redeemed ≥2000
defined daily dosages of thiazides over a 5 year period
were considered (in order to limit the study to those
adherent to regular treatment), this consumption was
associated with a 26% reduction in any fracture, a 19%
reduction in hip fracture, a 5% reduction in fracture of the
spine and a 31% reduction in forearm fractures. Moreover
a second study has suggested that forearm fractures may
be reduced by 37% in those using thiazide diuretics for
more than 8 years [24]. The results of a further large phar-
macoepidemiological study suggested a 20% reduction in
all fractures with the use of thiazide diuretic but also a
23% reduction with the use of beta blockers on their own
[21]. This has been confirmed recently but a benefit has
also been suggested for angiotensin converting enzyme
(ACE) inhibitors and calcium-Channel blockers [46]. This
raises the possibility that blood pressure reduction or con-
founding factors may be responsible for the benefits.
Conclusion
It is hoped that the HYVET fracture sub-study will provide
a clear answer to the benefit or otherwise of diuretic (inda-
pamide slow release 1.5 mg ± perindopril 2–4 mg) treat-
ment in the prevention of fractures in the very elderly
hypertensive. It is also possible that the findings of the
study will help determine the risks and benefits of treat-
ment and assist in the overall decision: to treat or not treat
the very elderly hypertensive subjects with a diuretic ±
ACE inhibitor?
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